Uniting Forces for Precision Cancer Therapies

TUM President Prof. Thomas F. Hofmann emphasized: "We need to accelerate the development of effective cancer therapies! This is why we are combining TUM’s excellence in natural sciences and medicine with the production of radioisotopes, such as Lutetium-177, at the FRM II research reactor, alongside ITM’s expertise as a leading radiopharmaceutical biotech company in the development and manufacturing of medical radiotherapeutics and diagnostics, and the top-tier medical care provided by our TUM University Hospital. Together, we aim to develop innovative radionuclide therapies for targeted cancer treatment, significantly improving treatment outcomes and quality of life for cancer patients."

Dr. Andrew Cavey, CEO of ITM, said: "TUM is a global leader in merging top-tier research, scientific innovation, and entrepreneurship. This agreement is the culmination of two decades of collaboration with TUM, and it will provide us with valuable access to their world-class institutes and clinics, advancing pioneering research in nuclear medicine. As we expand our pipeline of targeted radiopharmaceuticals, we look forward to working on future projects with TUM to further develop new treatment options for cancer patients."

Prof. Stephanie Combs, Dean of the TUM School of Medicine and Health and Board Member of the TUM University Hospital, stated: “In the interdisciplinary fight against cancer, nuclear medicine plays a particularly significant role. It is crucial for imaging the disease and its innovative treatment methods open up new opportunities for patients. That is why we are committed to researching new approaches. The unique collaboration between TUM and ITM offers unparalleled opportunities to combine ITM’s leading position in radioisotope production and drug development with the research expertise of our university hospital. I am very excited to provide our patients with the latest scientific advancements.”

Source: TUM